Heart attack drug may melt artery plaque

NCT ID NCT06372925

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 27, 2026 · Last updated May 23, 2026 · Updated 19 times

Summary

This study tests whether the drug inclisiran can reduce fatty plaque buildup in heart arteries after a heart attack. About 334 adults with high cholesterol and a recent heart attack will receive inclisiran or standard care. Doctors will use special imaging to measure plaque changes over one year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Hefei, Anhui, 230001, China
Novartis Investigative Site
RECRUITING

Fuzhou, Fujian, 350001, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510030, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510080, China
Novartis Investigative Site
RECRUITING

Shenzhen, Guangdong, 518000, China
Novartis Investigative Site
RECRUITING

Zunyi, Guizhou, 563000, China
Novartis Investigative Site
RECRUITING

Harbin, Heilongjiang, 150086, China
Novartis Investigative Site
RECRUITING

Zhengzhou, Henan, 450003, China
Novartis Investigative Site
RECRUITING

Wuhan, Hubei, 430060, China
Novartis Investigative Site
RECRUITING

Nanchang, Jiangxi, 330006, China
Novartis Investigative Site
RECRUITING

Changchun, Jilin, 130033, China
Novartis Investigative Site
RECRUITING

Dalian, Liaoning, 116023, China
Novartis Investigative Site
RECRUITING

Jining, Shandong, 272000, China
Novartis Investigative Site
RECRUITING

Xian, Shanxi, 710061, China
Novartis Investigative Site
RECRUITING

Chengdu, Sichuan, 610072, China
Novartis Investigative Site
RECRUITING

Wenzhou, Zhejiang, 325027, China
Novartis Investigative Site
RECRUITING

Beijing, 101149, China
Novartis Investigative Site
RECRUITING

Lanzhou, 730000, China
Novartis Investigative Site
RECRUITING

Tianjin, 300000, China

Conditions

Explore the condition pages connected to this study.

PLAQUE, ATHEROSCLEROTIC